• Chance Pharma reports NMPA acceptance of NDA for CXG87 budesonide / formoterol DPI, Phase 3 results

  According to Chance Pharmaceuticals, China’s National Medical Products Administration has accepted the company’s NDA for CXG87 budesonide / formoterol DPI for the treatment of asthma. The announcement emphasizes that the formulation is Chance’s own “improved… [Read more . . .]

• Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

  CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing… [Read more . . .]

• Intertek announces expansion of GMP stability storage facility

  CDMO Intertek has announced an expansion of a GMP stability storage facility near Cambridge, UK, noting that the expanded facility offers custom temperature and relative humidity conditions and is suitable for stability testing of a… [Read more . . .]

• RDD 2026 exhibitor preview

  As RDD 2026 is about to get underway in Phoenix, AZ, USA, some of the meeting sponsors and exhibitors are previewing their conference activities. As always, RDD is sponsored by dozens of organizations that offer… [Read more . . .]

• MannKind is developing ralinepag DPI (MNKD-1501) for United Therapeutics

  MannKind Corporation announced that it is developing a DPI formulation of MNKD-1501 ralinepag for the treatment of pulmonary arterial hypertension under an agreement with United Therapeutics under a 2018 licensing and collaboration agreement between the companies that… [Read more . . .]

• Merxin receives King’s Award for Enterprise, names new Head of Business Development

• Copley Scientific introduces new SRS 100i sample recovery system for inhaler testing

• 3P Innovation and Mikron Automation partner to offer DPI manufacturing systems

• Insilico Medicine gets clearance for Phase 1 trial of rentosertib (ISM001-055) inhalation solution

• Transpire Bio opens R&D facility in China

More news . . .